Guest: Hugh Tildesley, MD 


  Host: Lee Freedman, MD 



  
    Metformin is often the first line of therapy for patients with type 2 diabetes: it is relatively inexpensive, available, and has proven efficacy. However, metformin is contraindicated for patients with renal insufficiency, a common comorbidity in diabetes. Do the benefits of metformin outweigh the risks for those with renal insufficiency, or should we use caution when considering metformin for these patients? Dr. Hugh Tildesley, clinical professor in the department of medicine, division of endocrinology at the University of British Columbia at St. Paul's Hospital in Vancouver, Canada, considers the safety of metformin in patients with diabetes. What approach should clinicians use when considering metformin for patients with type 2 diabetes who have some degree of renal impairment? Dr. Lee Freedman hosts.  

Weighing Metformin's Benefits & Risks in Patients With Renal Insufficiency

ReachMD takes an in-depth look at diabetes, a disease identified in nearly 1 in 10 Americans, which upsets the lives of millions more. Even more disturbing, the rates of new cases of diagnosed diabetes have risen almost twofold during the past decade. Nutrition, exercise and genetics are all factors in how the disease affects children, adults and the elderly, but that's only the beginning. How are surgical options changing the way we think about the disease? How close are we to a cure for Type 1 diabetes? Are there treatment lessons we can take from community-based initiatives abroad? Tune in to gain insights for your practice.

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Health

Alternative Health

Self-Help

Sexuality

Fitness & Nutrition

Guest: Kevan C. Herold, MD 


Guest: Chantal Mathieu, MD, PhD 



  Experts in the immunopathology of type 1 diabetes discuss the epidemiology, non-genetic and genetic risk factors, and progression from preclinical to clinical stages of this disease. The discussion will emphasize the breakdown of immune tolerance that precedes type 1 diabetes and the subsequent pathogenetic role of islet autoantibodies responsible for its clinical manifestations. 

Type 1 Diabetes & the Role of Anti-CD3 Targeted Therapy

Host: John E. Anderson, MD 


  Host: John Buse, MD, PhD 


  Host: Carol Wysham, MD 



  
    The wintertime presents new challenges for patients with chronic diseases, specifically diabetes. But with the spread of COVID-19, how can we help keep our patients safe all winter long? Tune in to hear our Diabetes Discourse hosts Drs. Carol Wysham, John Buse, and John Anderson discuss strategies to effectively manage patients with diabetes during these winter months. Published December X, 2020

Managing Diabetes & COVID-19 in the Wintertime

Host: Linda Bernstein, Pharm.D. 



  
    In this episode of The Drug Report, pharmacist Dr. Linda Bernstein highlights some diabetes medications that have achieved or are pending approval for new indications pertaining to cardiovascular disease risk reduction.

A Look at Diabetes Drugs That Reduce the Risk of Cardiovascular Disease

Host: Linda Bernstein, Pharm.D. 



  
    On this episode of The Drug Report, pharmacist Dr. Linda Bernstein focuses on a recent CVS Health announcement of their new plan that allows employers and health plan sponsors to work within a formulary and plan design to offer all types of diabetes medications—including insulin—at zero-dollar out of pocket for their members without raising costs for the plan sponsor or increasing premiums or deductibles for all plan members.

A New Health Plan to Eliminate Diabetes Patients’ Out-of-Pocket Costs

Host: Janine Austin Clayton, MD 


Guest: A. Paul Chous, MA, OD, FAAO, CDE 


Guest: Anne Peters, MD 



  When it comes to protecting the vision of our patients with diabetes, the importance of taking assertive action cannot be ignored. But another key aspect that can unfortunately be easy to overlook is care collaboration. Featuring Dr. Janine Clayton, Dr. A. Paul Chous, and Dr. Anne Peters, this discussion will focus on how providers can work together to optimize patients’ eye health and minimize their risk of vision loss from diabetic retinopathy and diabetic macular edema. Vision loss caused by diabetic retinopathy can have a significant impact on a patient's quality of life. This activity emphasizes more assertive action in clinical practice for patient with diabetes. The acronym ASSERT-D is a reminder to Assess and Screen for Eye health and Refer or Treat patients with Diabetes.

Weighing Metformin's Benefits & Risks in Patients With Renal Insufficiency

Download our free app to listen on your phone